Table 1.
Comparison of the baseline demographics and clinical characteristics of patients with ampicillin-susceptible and ampicillin-resistant Enterococcus faecium bacteraemia
| Variables | Ampicillin susceptibility | P-value | |||
|---|---|---|---|---|---|
| Susceptible (n = 10) | Resistant (n = 103) | ||||
| Demographics | |||||
| Age, median (IQR) | 74 | (70–78) | 61 | (50–71) | 0.015 |
| Sex (males) | 6 | (60) | 57 | (55) | 1 |
| Nosocomial infection | 5 | (50) | 96 | (93) | 0.001 |
| ICU-acquired | 0 | (0) | 31 | (30) | 0.059 |
| Underlying disease | |||||
| Heart disease | 4 | (40) | 25 | (24) | 0.276 |
| Stroke/hemiplegia | 1 | (10) | 8 | (7.8) | 0.580 |
| Chronic pulmonary disease | 2 | (20) | 8 | (7.8) | 0.216 |
| Systemic autoimmune diseases | 0 | (0) | 12 | (12) | 0.596 |
| Chronic kidney disease | 2 | (20) | 13 | (13) | 0.620 |
| Diabetes mellitus | 2 | (20) | 25 | (24) | 1 |
| Liver disease | 1 | (10) | 50 | (49) | 0.022 |
| Hematological malignancy | 1 | (10) | 25 | (24) | 0.449 |
| Solid tumour | 5 | (50) | 41 | (40) | 0.738 |
| Prior operation (6 m) | 1 | (10) | 51 | (50) | 0.020 |
| Indwelling devices | |||||
| Central venous catheter | 2 | (20) | 52 | (51) | 0.097 |
| Arterial line | 0 | (0) | 30 | (29) | 0.060 |
| Urinary devices | 1 | (10) | 33 | (32) | 0.277 |
| Mechanical ventilation | 0 | (0) | 23 | (22) | 0.209 |
| Bile duct devices | 1 | (10) | 24 | (23) | 0.454 |
| Surgical drain | 1 | (10) | 41 | (40) | 0.088 |
| Immunosuppression | |||||
| Solid organ transplantation | 0 | (0) | 33 | (32) | 0.033 |
| BMT/HSCT | 1 | (10) | 10 | (9.7) | 1 |
| Neutropenia | 0 | (0) | 22 | (21) | 0.205 |
| Chemotherapy (30 days) | 3 | (30) | 26 | (25) | 0.715 |
| Immunosuppressant | 2 | (20) | 60 | (58) | 0.041 |
| Prior antibiotic exposure (30 days) | 9 | (90) | 100 | (97) | 0.313 |
| Penicillins | 2 | (20) | 60 | (58) | 0.041 |
| Cephalosporins | 9 | (90) | 91 | (88) | 1 |
| Carbapenems | 1 | (10) | 54 | (52) | 0.016 |
| Quinolones | 5 | (50) | 47 | (46) | 1 |
| Glycopeptides | 1 | (10) | 43 | (42) | 0.086 |
| Sulfamethoxazole/Trimethoprim | 0 | (0) | 53 | (52) | 0.002 |
| Days from admission to onset, median (IQR) | 3 | (1–43) | 51 | (18–91) | 0.010 |
| Prior hospitalisation (1 year) | 10 | (100) | 69 | (67) | 0.031 |
| Prior ICU admission (1 year) | 0 | (0) | 49 | (48) | 0.005 |
| Prior enterococcal isolation (1 year) | 2 | (20) | 48 | (47) | 0.181 |
| Source of bacteraemia | |||||
| Intra-abdominal | 5 | (50) | 34 | (33) | 0.310 |
| Catheter-related bloodstream infection | 1 | (10) | 11 | (11) | 1 |
| Febrile neutropenia | 0 | (0) | 5 | (4.9) | 1 |
| Urinary tract | 1 | (10) | 6 | (5.8) | 0.487 |
| Unknown | 3 | (30) | 44 | (43) | 0.518 |
| Other | 0 | (0) | 3 | (2.9) | 1 |
| Pitt bacteraemia score, median (IQR) | 1 | (0–2) | 2 | (1–6) | 0.056 |
| Charlson comorbidity index, median (IQR) | 3 | (2–5) | 4 | (3–5) | 0.386 |
Data represent the number (%) of patients unless otherwise indicated.
IQR, interquartile range; ICU, intensive care unit; BMT, bone marrow transplantation; HSCT, hematopoietic stem cell transplantation.